Clinical and urodynamic efficacy and safety of different modes of pharmacotherapy for men with LUTS/BPH depending of their androgenic status
Abstract
Background. Research objective is an efficiency and safety analysis of different ways of treatment of lower urinary tract symptoms/benign prostatic hyperplasia (LUTS/BPH), including androgen substitutive therapy. Methods. The results of the survey and conservative treatment of 187 men with LUTS/BPH were analyzed. Monotherapy α1-blocker, 5α-reductase inhibitor and plant complex received 40, 35 and 30 patients, respectively. Another 40 people received combination therapy (α1-blocker and 5α-reductase inhibitor) and 42 patients with age-related hypogonadism additionally received the testosterone undecenoate. Results. The efficacy of standard medical therapy without androgen status of patients was on average 70.2 %. Additional androgen substitutive therapy of testosterone with the undecanoate contributed significantly more pronounced therapeutic effect in hypogonadal men. Conclusions. The study confirmed the high clinical and urodynamic efficacy and safety of a combination of standard treatment and androgen substitutive therapy in hypogonadal men with LUTS/BPH.
About the Authors
O. I. Bratchikov
Kursk State Medical University
Russian Federation
Russian Federation
I. A. Tyuzikov
Clinic of Professor Kalinichenko
Russian Federation
Russian Federation
E. A. Shumakova
Kursk State Medical University
Russian Federation
Russian Federation
A. A. Gres
Belorussian Medical Academy of Postgraduate Education
Russian Federation
Russian Federation
S. A. Churaev
Kursk State Medical University
Russian Federation
Russian Federation
References
1. Братчиков О.И., Шумакова Е.А., Хмарук А.П., Михайлов Д.В. Оптимизация методов медикаментозного лечения больных аденомой предстательной железы // Человек и его здоровье: Курский научно-практический вестник. 2011. № 3. С. 34-41.
2. Братчиков О.И., Тюзиков И.А., Шумакова Е.А. [и др.] Клиникоэпидемиологические корреляции возрастного андрогенного дефицита и СНМП/АПЖ у мужчин // Человек и его здоровье: Курский научно-практ. вестник. 2014. № 4. С. 40-45.
3. Братчиков О.И., Тюзиков И.А., Шумакова Е.А. [и др.] Влияние различных режимов фармакотерапии на объем предстательной железы и остаточной мочи у мужчин с СНМП/ АПЖ в зависимости от их андрогенного статуса // Человек и его здоровье: Курский научно-практический вестник. 2015. № 1. С. 10-17.
4. Попков В.М., Братчиков О.И., Блюмберг Б.И. Клинико-диагностическое значение маркеров клеточного обновления и эндокринных клеток при заболеваниях предстательной железы // Тихоокеанский медицинский журнал. 2011. № 1. С. 29-33.
5. Bratchikov O., Hambaryan A. Is the obstructive uropathy a sequence of vascular disorders in patients with BPH? // European urology supplements. 23 Annual EAU Congress. Milan, 2008. Vol. 7, Is. 3, P. 236.
6. Hafez B., Hafez E.S. Andropause: endocrinology, erectile dysfunction, and prostate pathophysiology // Arch. Androl. 2004. Vol. 50, No. 2. P. 45-68.
7. Haider A., Gooren L.J., Padungtod P., Saad F. Concurrent improvement of the metabolic syndrome and lower urinary tract symptoms upon normalisation of plasma testosterone levels in hypogonadal elderly men // Andrologia. 2009. Vol. 41. P. 7-13.
8. Karazindiyanoğlu S., Cayan S. The effect of testosterone therapy on lower urinary tract symptoms/bladder and sexual functions in men with symptomatic late-onset hypogonadism // Aging Male. 2008. Vol. 11, No. 3. P. 146-149.
9. Koritsiadis G., Stravodimos K., Mitropoulos D. Androgens and bladder outlet obstruction: a correlation with pressure-flow variables in a preliminary study // BJU Int. 2008. Vol. 101. P. 1542-1546.
10. Lee J.H., Kim Y., Park Y.W, Lee D.G. Relationship between benign prostatic hyperplasia/lower urinary tract symptoms and total serum testosterone level in healthy middle-aged eugonadal men // J. Sex. Med. 2014. Vol. 11, No. 5. P. 1309-1315.
11. Maserejian N.N., Chen S., Chiu G.R. Treatment status and progression or regression of lower urinary tract symptoms among adults in a general population sample // J. Urol. 2013. Vol. 9. pii: S0022-5347(13)04861-1. doi: 10.1016/j.juro.2013.07.005 [Epub ahead of print].
12. Shigehara K., Namiki M. Late-onset hypogonadism syndrome and lower urinary tract symptoms // Korean J. Urol. 2011. Vol. 52, No. 10. P. 657-663.
Review
For citations:
Bratchikov O.I., Tyuzikov I.A., Shumakova E.A., Gres A.A., Churaev S.A. Clinical and urodynamic efficacy and safety of different modes of pharmacotherapy for men with LUTS/BPH depending of their androgenic status. Pacific Medical Journal. 2016;(1):29-32. (In Russ.)
Views:
338
Email this article 